Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2381446 | 0.98 | TACR1 (0.61) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL1916659 | 0.87 | ACHE (0.56) | TACR1SIGMAR1ACHEBCHEBACE1 | |
| Bromide SCHEMBL548941 | 0.86 | ACHE (0.54) | TACR1SIGMAR1ACHEBCHEBACE1 | |
| SCHEMBL385325 | 0.81 | TACR1 (0.62) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL16836134 | 0.81 | SIGMAR1 (0.64) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL24036210 | 0.81 | TACR1 (0.62) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL6943959 | 0.81 | TACR1 (0.62) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL467266 | 0.81 | TACR1 (0.62) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL6041583 | 0.79 | TACR1 (0.61) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL1400959 | 0.79 | TACR1 (0.61) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-09 | — | — | US | disclosed |
| US-9475782-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | disclosed |
| EP-1716127-B1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT LABORATORIES (US) | 2013-12-05 | — | — | US | disclosed |
| US-8524736-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARMETHEON, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524736-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARMETHEON, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8481576-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8431604-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-04-30 | — | — | US | disclosed |
| EP-2194053-B1 | Methoxy piperidine derivatives for use inr the treatment of gastrointestinal and central nervous system disorders | ARMETHEON INC (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2194053-B1 | Methoxy piperidine derivatives for use inr the treatment of gastrointestinal and central nervous system disorders | ARMETHEON INC (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-1578341-A2 | MODULATION OF CCR4 FUNCTION | Tularik Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2005082871-A2 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2005-09-09 | — | — | WO | disclosed |
| US-20050197363-A1 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS (US) | 2005-09-08 | — | — | US | disclosed |
| US-20050176757-A1 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005068461-A1 | STEREOISOMERIC COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS (US) | 2005-07-28 | — | — | WO | disclosed |
| US-20040039035-A1 | Modulation of CCR4 function | TULARIK INC. | 2004-02-26 | — | — | US | disclosed |
| US-20030018022-A1 | Ccr4 antagonists | TULARIK INC. | 2003-01-23 | — | — | US | disclosed |
| WO-2002094264-A1 | CCR4 ANTAGONISTS | TULARIK INC. (US) | 2002-11-28 | — | — | WO | disclosed |
| US-20020173524-A1 | Modulation of CCR4 function | TULARIK INC. (US) | 2002-11-21 | — | — | US | disclosed |
| WO-2002030358-A2 | MODULATION OF CCR4 FUNCTION | TULARIK INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176757-A1 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | CCKBR, GRPR, HRH2 | TACR1 64/4885SIGMAR1 1311/4885GRIN1 378/4885 |
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | TACR1 211/4885SIGMAR1 489/4885GRIN1 115/4885 |
| US-20030018022-A1 | Ccr4 antagonists | CCR4, CCR1, CCR3 | TACR1 318/4885SIGMAR1 1327/4885GRIN1 1589/4885 |
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, GRK5 | TACR1 251/4885SIGMAR1 546/4885GRIN1 100/4885 |
| US-20020173524-A1 | Modulation of CCR4 function | CCR4, CCR1, CCR3 | TACR1 757/4885SIGMAR1 1916/4885GRIN1 1130/4885 |
| US-20040039035-A1 | Modulation of CCR4 function | CCR4, CCR1, CCR3 | TACR1 757/4885SIGMAR1 1916/4885GRIN1 1130/4885 |
| US-20050197363-A1 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | CCKBR, GRPR, HRH2 | TACR1 64/4885SIGMAR1 1311/4885GRIN1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.